In-depth method comparison by Dutch group shows that sphingotec's proprietary kidney function biomarker penKid(R) is currently the most accurate surrogate marker for true glomerular filtration rate in patients with renal impairment
Data by PRONOBURNS group show that penKid(R) accurately predicts acute kidney injury (AKI) in patients with burns, adding benefit on top of standard testing
Since January 2020, an automated CE-marked IVD penKid(R) assay developed for sphingotec's proprietary point-of-care platform Nexus IB10 is available for use in critical care settings

HENNIGSDORF and BERLIN, GERMANY / ACCESSWIRE / February 19, 2020 / Diagnostics company SphingoTec GmbH ("sphingotec", Hennigsdorf Germany) today announced the publication of two studies demonstrating that its kidney function biomarker Proenkephalin (penKid(R)) is the most accurate surrogate for assessing true glomerular filtration rate (true GFR) and is reliably predictive for acute kidney injury (AKI) in patients with severe burns. Although AKI is a major complication in critically ill patients, current diagnostic standard methods do not properly and timely diagnose impaired renal function. The two recently published studies add to the rapidly growing body of evidence suggesting that penKid(R) can address this highly unmet diagnostic need.

In Shock1, a team headed by Prof. Peter Pickkers from Radboud UMC (Nijmegen, The Netherlands) confirmed by in-depth diagnostic method comparison in patients with impaired kidney function that penKid(R) levels properly reflect kidney function. While today's standard of care uses estimations of the glomerular filtration rate (eGFR) to assess renal impairment, the current study shows that these methods overestimate true GFR with over 30%. The published findings demonstrate that penKid(R) can add value by properly reflecting true GFR that can otherwise only be measured using in vivo clearance of iohexol, an invasive method too laborious and time-consuming for clinical routine use.

Another study published in the Journal of Burns2 reports for the first time that high penKid(R) plasma levels at admission to the intensive care unit (ICU) were associated with the risk for developing AKI in patients with severe burns, where mortality rates range from 30-70%.

The new data suggest, that the current renal function- and AKI standard markers should be complemented with penKid(R) values for accurately quantifying the kidney function in critically ill patients. Dr. Andreas Bergmann, CEO of sphingotec, commented: "penKid(R) is an early renal function biomarker that is not biased by co-morbidities while reflecting true GFR. penKid(R) has been tested for the first time to identify ICU patients with severe burns that need rapid and aggressive intervention to prevent mortality caused by AKI."

To support timely treatment decisions that are likely to improve patient management in critical care patients, sphingotec launched a fully automated CE-IVD-marked penKid(R) assay on its Nexus IB10 platform in January 2020. This new test complements a wide-range of assays for acute care settings that are already available on this widely used point-of-care platform that can be flexibly deployed in near-patient as well as laboratory settings.

Beunders, R. et al., Proenkephalin compared to conventional methods to assess kidney function in critically ill sepsis patients, Shock,, doi:10.1097/SHK.0000000000001510
Depret, F. et al, PenKid measurement at admission is associated with outcome in severely ill burn patients, J.Burns, doi: doi.org/10.1016/j.burns.2020.01.002

About sphingotec 
 SphingoTec GmbH ("sphingotec"; Hennigsdorf near Berlin, Germany) develops and markets innovative in vitro diagnostic (IVD) tests for novel and proprietary biomarkers for the diagnosis, prediction and monitoring of acute medical conditions, such as sepsis, acute heart failure, circulatory shock, and acute kidney injury in order to support patient management and provide guidance for treatment strategies. sphingotec's proprietary biomarker portfolio includes Bioactive Adrenomedullin (bio-ADM(R)), a unique biomarker for real-time assessment of endothelial function in conditions like sepsis or congestive heart failure, Proenkephalin (penKid(R)), a unique biomarker for real-time assessment of kidney function, and Dipeptidyl Peptidase 3 (DPP3), a unique biomarker for cardio-renal pathway disruptions leading to acute organ dysfunction. In addition, sphingotec develops a portfolio of novel biomarkers, which predict the risks of developing obesity, breast cancer and cardiovascular diseases. IVD tests for sphingotec's proprietary biomarkers are made available as sphingotest(R) microtiterplate tests as well as point-of-care tests on the Nexus IB10 immunoassay platform by sphingotec's subsidiary Nexus Dx Inc. (San Diego, CA, USA) alongside a broad menu of IB10 tests for established biomarkers for acute and critical care.

About penKid(R)
sphingotest(R) penKid(R) measures proenkephalin (penKid(R)), a stable fragment of the kidney stimulating hormone enkephalin. penKid(R) has been demonstrated to be a real-time surrogate biomarker for glomerular filtration rate, the gold standard to assess renal function. Measuring penKid(R) blood concentrations allows for timely information on kidney function in critically ill patients. Early assessment of worsening and improving of renal function on intensive care units and in emergency departments allows adjustment of nephrotoxic drug administration and the initiation of kidney-protective strategies to prevent acute kidney injury and thereby improve outcomes.

About Nexus Dx Inc. and the IB10 Platform 
Nexus Dx Inc., a wholly-owned subsidiary of sphingotec, headquartered in San Diego, CA, USA, is a global provider of a near patient testing system and advanced diagnostic solution. The company is improving patient care by providing the medical community with rapid and reliable information at the point of care (POC), delivering patient information when and where it is needed most. The company has invested over $160m to develop and market the IB10 analyzer system which, without the need for sample preparation, automatically separates plasma from whole blood with subsequent reliable and quantitative detection of biomarkers in the plasma by means of antibodies. With a hands-on-time of less than 3 minutes the easy-to-use system provides in only 20 minutes test results for biomarkers that are crucial in the management of critical care patients. The portfolio of IB10 assays includes tests for established critical care parameters such as Procalcitonin, Troponin I, CK-MB, Myoglobin, NT-proBNP, and D-Dimer as well as tests for sphingotec's proprietary biomarkers such as DPP3, an assay for Dipeptidyl Peptidase 3, a unique and proprietary biomarker for cardio-renal pathway disruptions leading to acute organ dysfunction, and Proenkephalin (penKid(R)), a unique and proprietary biomarker for real-time assessment of kidney function. An IB10 assay for bioactive Adrenomedullin (bio-ADM(R)), a unique and proprietary biomarker for endothelial function is expected to be launched later in 2020. 

Contact 
SphingoTec GmbH
Ruxandra Lenz
Neuendorfstr. 15a
16761 Hennigsdorf
Germany
Tel. +49-3302-20565-0
press@sphingotec.de
www.sphingotec.com
 
SOURCE: SphingoTec GmbH via EQS Newswire

ReleaseID: 576958

VANCOUVER, BC / ACCESSWIRE / February 19, 2020 / Ximen Mining Corp. (TSXV:XIM)(FRA:1XMA)(OTCQB:XXMMF) (the "Company" or "Ximen") wishes to announce that is has verified gold assays for previous drill core from the Kenville gold mine at Nelson in southern BC.

As part of on-going metallurgical studies on material from the Kenville gold mine, Ximen submitted a series of samples collected from drill core and bulk sample material that was generated by previous operators. A total of 13 drill core samples were collected from selected intercepts obtained in the years 2007 to 2011 inclusive. In addition, assays were completed on two composite samples labelled as "High Grade" and "Low grade" that will be used to create a metallurgical test sample. Assay results are provided in the table below.

Hole/Sample

From
(m)

To
(m)

Length
(m)

Original
Sample
Number

New
Sample
Number

Original
Value
Gold g/t

Check
Assay
Gold g/t

Difference
%

AK07-05

291.70

292.70

1.00

43465

V112451

15.90

12.23

-23%

AK08-07

234.70

235.20

0.50

43305

V112452

44.71

28.38

-37%

AK08-18

216.71

217.03

0.32

190029

V112453

29.20

17.71

-39%

AK08-20

84.42

84.64

0.22

190044

V112454

37.60

14.23

-62%

AK08-30

103.20

103.33

0.13

190336

V112455

14.90

8.51

-43%

KW10-02

202.88

203.45

0.57

I985502

V112456

36.20

35.2

-3%

KE09-10

456.15

457.03

0.88

A085823

V112457

14.35

10.42

-27%

KE09-10

457.03

457.97

0.94

A085824

V112458

43.60

47.32

9%

KE10-12

346.02

346.55

0.53

I984091

V112459

12.27

13.64

11%

KE10-15

228.49

228.69

0.20

I984182

V112460

113.08

191.13

69%

KE10-16

361.86

362.74

0.88

J294131

V112461

88.10

45.74

-48%

KE11-22

263.86

264.65

0.79

K242405

V112462

14.20

21.12

49%

KE10-12

387.79

387.99

0.20

I984094

V112360

62.19

55.02

-12%

Low Grade Composite

26.39

High Grade Composite

55.28

Graph showing check assay results for Kenville drill core samples

As shown in the table above, the drill core assay results show a wide range of differences. The average difference between the check and original assays is -12%. The high variability in assay results is typical of gold vein deposits and is likely due to a nugget effect caused by the presence of coarse gold grains in the mineralized material. Also, the original values were determined by various methods including 30 gram fire assay or the metallics sieve method and as such are not exactly comparable to the check assays. Note that the average grade of the check assays is 38.51 whereas the average of the original values is 40.48 grams per tonne gold, a difference of only -5%. In addition, 11 of 13 (85%) of the check assays are within +/- 50 percent of the original values (see graph). The check assays compare reasonably for this type of coarse gold bearing mineralization and are therefore considered to verify the original drill core assays.

For the composite samples, the results indicate relatively high gold contents. Compared to the average grade historically mined from the deposit (12.8 grams per tonne gold), the "Low Grade" composite assay is about 2 times higher and the "High Grade" composite assayed about four times higher.

Check assays were performed by MSALABS at Langley, BC, an independent commercial laboratory, accredited with ISO/IEC Standard 17025. Samples were prepared pulverized a 250 gram split to 85% passing 75 microns. Gold analyses were performed on 30 gram subsamples. Sample # 112460 was subjected to a duplicate 30g high grade fire assay (with a detection range of 0.05 – 1000 g/t Au) with gravimetric finish while the remaining samples were each subjected to a single 30g ore grade fire assay (with a detection range of 0.01 to 100 g/t Au) with AA finish.

Dr. Mathew Ball, P.Geo., VP Exploration for Ximen Mining Corp. and a Qualified Person as defined by NI 43-101, approved the technical information contained in this News Release.

On behalf of the Board of Directors,

"Christopher R. Anderson"

Christopher R. Anderson,
President, CEO and Director
604 488-3900

Investor Relations:

Sophy Cesar,
604-488-3900,
ir@XimenMiningCorp.com

About Ximen Mining Corp.

Ximen Mining Corp. owns 100% interest in three of its precious metal projects located in southern BC. Ximen`s two Gold projects The Amelia Gold Mine and The Brett Epithermal Gold Project. Ximen also owns the Treasure Mountain Silver Project adjacent to the past producing Huldra Silver Mine. Currently, the Treasure Mountain Silver Project is under a option agreement. The option partner is making annual staged cash and stocks payments as well as funding the development of the project. The company has recently acquired control of the Kenville Gold mine near Nelson British Columbia which comes with surface and underground rights, buildings and equipment.

Ximen is a publicly listed company trading on the TSX Venture Exchange under the symbol XIM, in the USA under the symbol XXMMF, and in Frankfurt, Munich, and Berlin Stock Exchanges in Germany under the symbol 1XMA and WKN with the number as A2JBKL.

This press release contains certain "forward-looking statements" within the meaning of Canadian securities legislation, including statements regarding the receipt of TSX Venture Exchange approval and the exercise of the Option by Ximen. Although the Company believes that such statements are reasonable, it can give no assurance that such expectations will prove to be correct. Forward-looking statements are statements that are not historical facts; they are generally, but not always, identified by the words "expects," "plans," "anticipates," "believes," "intends," "estimates," "projects," "aims," "potential," "goal," "objective," "prospective," and similar expressions, or that events or conditions "will," "would," "may," "can," "could" or "should" occur, or are those statements, which, by their nature, refer to future events. The Company cautions that forward-looking statements are based on the beliefs, estimates and opinions of the Company's management on the date the statements are made and they involve a number of risks and uncertainties. Consequently, there can be no assurances that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Except to the extent required by applicable securities laws and the policies of the TSX Venture Exchange, the Company undertakes no obligation to update these forward-looking statements if management's beliefs, estimates or opinions, or other factors, should change. Factors that could cause future results to differ materially from those anticipated in these forward-looking statements include the possibility that the TSX Venture Exchange may not accept the proposed transaction in a timely manner, if at all. The reader is urged to refer to the Company's reports, publicly available through the Canadian Securities Administrators' System for Electronic Document Analysis and Retrieval (SEDAR) at www.sedar.com for a more complete discussion of such risk factors and their potential effects.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of securities in any state in the United States in which such offer, solicitation or sale would be unlawful.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

SOURCE: Ximen Mining Corp.

ReleaseID: 576923

Arcology to Demonstrate Its Advantages with Utilizing One of the Most Successful Games on Ethereum

VANCOUVER, BC / ACCESSWIRE / February 19, 2020 / Codebase Ventures Inc. ("Codebase" or the "Company") (CSE:CODE)(FSE:C5B)(OTCQB:BKLLF), an investment company, is pleased to announce that the Arcology technical team is launching its comprehensive testing of the high profile Ethereum game called CryptoKitties on its own internal testnet.

CryptoKitties is a very well-known game that runs on the Ethereum network, and which has caused serious network congestions because of its transaction volume. Using this example to illustrate Arcology's speed and scalability provides a purposeful comparison and validation of the platform's capabilities.

Multiple blockchain technology projects have endeavoured to solve the scalability issue with different approaches with no demonstrated, major success to date. Arcology has a very unique solution to address that problem, featuring the following capabilities:

Arcology allows multiple transactions to be processed in parallel
Transaction processing can scale up linearly based upon number of computers available
Fully compatible with Ethereum platform
Popular Ethereum applications like CryptoKitties can work on Arcology smoothly
Ethereum developers can start to work on Arcology right away
Minimized migration costs

The purpose of this test is to demonstrate Arcology's technical advantages, scalability and transaction per second speed.

"CryptoKitties was the major event within the whole blockchain industry when the overall challenge of scalability became evident. This Arcology test serves as a showcase, with the goal of demonstrating Arcology's technical superiority. It is an internal test, a prelude for our public benchmarking and demonstration in the near future," said Mr. Laurent Zhang, President of Arcology.

About Codebase Ventures Inc.

Codebase Ventures Inc. is an investment company, led by technology and business experts who invest early in great ideas in sectors that have significant upside, including the cannabis sector. We operate from the understanding that technology is always evolving, bringing early opportunities for strategic investments that can deliver the exponential returns to our shareholders. We seek out and empower the innovators who are building tomorrow's standards with platforms, protocols and innovations – not just products. We invest early, support those founders, take their ideas to market and work tirelessly to help them realize their vision.

Neither the Canadian Securities Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release.

For further information, please contact:

George Tsafalas or Ivy Lu

Investor Relations

Telephone: 1 (778) 806-5150

E-mail: IR@codebase.ventures

Forward Looking Statements

Certain information set forth in this news release may contain forward-looking statements that involve substantial known and unknown risks and uncertainties. All statements other than statements of historical fact are forward-looking statements, including, without limitation, statements regarding future financial position, business strategy, use of proceeds, corporate vision, proposed acquisitions, partnerships, joint-ventures and strategic alliances and co-operations, budgets, cost and plans and objectives of or involving the Company. Such forward-looking information reflects management's current beliefs and is based on information currently available to management. Often, but not always, forward-looking statements can be identified by the use of words such as "plans", "expects", "is expected", "budget", "scheduled", "estimates", "forecasts", "predicts", "intends", "targets", "aims", "anticipates" or "believes" or variations (including negative variations) of such words and phrases or may be identified by statements to the effect that certain actions "may", "could", "should", "would", "might" or "will" be taken, occur or be achieved. A number of known and unknown risks, uncertainties and other factors may cause the actual results or performance to materially differ from any future results or performance expressed or implied by the forward-looking information. These forward-looking statements are subject to numerous risks and uncertainties, certain of which are beyond the control of the Company including, but not limited to, the impact of general economic conditions, industry conditions and dependence upon regulatory approvals. Readers are cautioned that the assumptions used in the preparation of such information, although considered reasonable at the time of preparation, may prove to be imprecise and, as such, undue reliance should not be placed on forward-looking statements. The Company does not assume any obligation to update or revise its forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by securities laws.

SOURCE: Codebase Ventures Inc.

ReleaseID: 576916

*1: Among stacked Event-based vision sensors, as of announcement on February 19, 2020.

PARIS, FRANCE / ACCESSWIRE / February 19, 2020 / Prophesee S.A. and Sony Corporation today announced they have jointly developed a stacked Event-based vision sensor with the industry's smallest*1 4.86μm pixel size and the industry's highest*1 124dB (or more) HDR performance.

Click Here to View Full Release including press-ready images, quotes, bios, and more.

Key Takeaways

The stacked event-based vision sensor is the industry's smallest*¹ 4.86μm pixel size and the highest*¹ 124dB (or more) HDR performance.

This joint development combines technical features of Sony's stacked CMOS image sensor, resulting in small pixel size and excellent low light performance that are achieved by the use of Cu-Cu connection*², with Prophesee's MetavisionⓇ Event-based vision sensing technologies leading to fast pixel response, high temporal resolution and high throughput data readout.

The newly developed sensor is suitable for various machine vision applications, such as detecting fast moving objects in a wide range of environments and conditions.

About Prophesee

Prophesee develops the world's most advanced neuromorphic vision systems. The company's Event-Based approach to machine vision allows for significant reductions of power, latency and data processing requirements as compared to traditional frame-based vision systems.

Prophesee's sensors and algorithms are designed to mimic the way biological eyes and brains work – with the goal to significantly improve performance, power and data efficiency of artificial vision systems in areas such as autonomous vehicles, industrial automation, IoT, security and surveillance, and AR/VR.

Contacts

Mike Sottak
mike@wiredislandpr.com
+1 650 248 9597
Prophesee – US contact

Romain Griere
rgriere@image7.fr
+33 (0)7 86 53 17 29
Prophesee – Europe contact

Prophesee – Global Contact
press@prophesee.ai

SOURCE: Prophesee

ReleaseID: 576913

RIVERSIDE, CA / ACCESSWIRE / February 18, 2020 / Drip Creationz is a clothing company that specializes in footwear, apparel, and accessories. The company is well known for producing sturdy and durable products. This clothing company is one of the largest in the world with a substantial social media following.

Drip Creationz has its headquarters near Riverside California and specializes in the design, development, production and worldwide distribution of footwear, apparels, and accessories has made it a mission to ensure that people can be dressed in a classy and stylish manner.

Co-founded by the trio of Frankie Quiroz, Ilene Arellano, and Brian Porter in 2017, Drip Creationz has quickly risen to become one of the most prosperous clothing companies in the world. In fact, its CEO says, " Our products are the best in the world, and we have a vast array of customers for whom we provide classy and quality products." This statement is not surprising considering the fact that the company custom makes products upon receiving orders and hand stitches them to sterling perfection, with the result that its customers are left satisfied with the product.

With a whopping 50,000 satisfied customers and over 600,000 followers on Instagram alone, it is not surprising that the company is as prosperous as it is. Drip Creationz has a social media followership of over a hundred million people and has the privilege of working with over 500 major social media influencers. Some of these influencers are Sommer Ray, Tana Mongeau, Jake Paul, Logan Paul, and celebrities like Ruby Rose, McKenna Grace, Jenna Dewan, and Greg Sulkin.

Drip Creationz can be compared to the likes of Guess, Pacsun, Coachella, and World star hip hop. The company is on Instagram with the ID, @DRIPCREATIONZ. It is also on TikTok as @DRIPCREATIONZ. It is quite clear that the sky is the limit for Drip Creationz as it continues to provide people with durable and classy wear.

Media contact

Company Name: Drip Creationz
Contact: Frankie Quiroz
Email: DRIPCREATION@GMAIL.COM
Website: https://www.dripcreationz.com/

SOURCE: Drip Creationz

ReleaseID: 576952